Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Furrer

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
HIV Medicine|January 22, 2011
Clinical relevance of cytomegalovirus viraemia(*,†)E Boffi El Amari, C Combescure, S Yerly, et al.
HIV Medicine|October 28, 2017
European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summaryS De Wit, M Battegay, A D'Arminio Monforte, et al.
The New England Journal of Medicine|February 24, 2001
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study GroupsB Ledergerber, A Mocroft, P Reiss, et al.
HIV Medicine|May 8, 2008
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control studyD M Wunder, C A Fux, N A Bersinger, et al.
HIV Medicine|September 25, 2012
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyR Weber, M Ruppik, M Rickenbach, et al.
Infection|January 7, 2000
Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: a countrywide 9-year cohort study. Swiss HIV Cohort StudyP Sudre, G E Pfyffer, T Bodmer, et al.
HIV Medicine|August 15, 2006
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort StudyT R Glass, C Ungsedhapand, M Wolbers, et al.
HIV Medicine|February 26, 2015
Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialA C Achhra, A Mocroft, M J Ross, et al.
Clinical Pharmacology and Therapeutics|January 20, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individualsM Rotger, H Tegude, S Colombo, et al.
JAMA|December 22, 1999
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort StudyB Ledergerber, M Egger, V Erard, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
HIV Medicine|January 22, 2011
Clinical relevance of cytomegalovirus viraemia(*,†)E Boffi El Amari, C Combescure, S Yerly, et al.
HIV Medicine|October 28, 2017
European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summaryS De Wit, M Battegay, A D'Arminio Monforte, et al.
The New England Journal of Medicine|February 24, 2001
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study GroupsB Ledergerber, A Mocroft, P Reiss, et al.
HIV Medicine|May 8, 2008
Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control studyD M Wunder, C A Fux, N A Bersinger, et al.
HIV Medicine|September 25, 2012
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyR Weber, M Ruppik, M Rickenbach, et al.
Infection|January 7, 2000
Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: a countrywide 9-year cohort study. Swiss HIV Cohort StudyP Sudre, G E Pfyffer, T Bodmer, et al.
HIV Medicine|August 15, 2006
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort StudyT R Glass, C Ungsedhapand, M Wolbers, et al.
HIV Medicine|February 26, 2015
Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialA C Achhra, A Mocroft, M J Ross, et al.
Clinical Pharmacology and Therapeutics|January 20, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individualsM Rotger, H Tegude, S Colombo, et al.
JAMA|December 22, 1999
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort StudyB Ledergerber, M Egger, V Erard, et al.
Pageof 10